Soficitinib

N/A

Report date: 2026/05/07 20:00:36
NME

Base Information

Drug NameSoficitinib
Drug Alias NameICP-332
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase 2 inhibitors
TargetsTyrosine-protein kinase 2
Therapy Area/IndicationsPlaque psoriasisPrurigo NodularisChronic Urticaria +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesInnoCare Pharma Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesInnoCare Pharma IncGuangzhou Innocare Pharma Tech Co LtdInnoCare Pharma Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPrurigo NodularisChronic Urticaria +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A